Earnings Releases

Beeline Holdings, Inc. reported the three months ending March 31, 2024 results: revenue $2.5 million, net income $1.3 million.

“Gross sales for the three months ending March 31, 2024 decreased to $2.5 million from $2.9 million for the three months ending March 31, 2023. Higher digital printing sales were offset by lower mobile canning and spirits sales. Spirits sales fell due primarily to the Company’s bulk sale of 250 barrels for gross proceeds of $0.6 million during the three months ended March 31, 2023. Gross profit for the three months ending March 31, 2024 decreased to $0.2 million from $0.6 million for the three months ending March 31, 2023. Consolidated gross margin was 8% and 22% for the three months ending March 31, 2024 and 2023, respectively. Craft C+P gross margin increased due to higher printed can volumes. Spirits gross margin decreased due to gross profit of $0.5 million from bulk sales of barrels during the three months ended March 31, 2023. Operating costs for the three months ending March 31, 2024 decreased to $0.2 million from $0.6 million for the three months ending March 31, 2023 primarily”

CalciMedica, Inc. reported the first quarter ended March 31, 2024 results: net income $0.1 million, EPS $0.01 per share (basic and diluted).

“With the impact of a $5.6 million non-cash gain from the fair value adjustment of the warrant liability, net income was $0.1 million, or $0.01 per share (basic and diluted) for the three months March 31, 2024.”

Smart Sand, Inc. reported first quarter ended March 31, 2024 results: revenue $83.1 million, net income net loss of $0.2 million, EPS $(0.01) per basic and diluted share.

“in such filing. --- EX-99.1 (EX-99.1) --- Smart Sand, Inc. Announces First Quarter 2024 Results • 1Q 2024 total tons sold of approximately 1.3 million • 1Q 2024 revenue of $83.1 million • 1Q 2024 net loss of $(0.2) million • 1Q 2024 adjusted EBITDA of $9.3 million YARDLEY, Pennsylvania, May 13, 2024 – Smart Sand, Inc. (NASDAQ: SND) (the “Company” or “Smart”

Annexon, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 13, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2024.”

CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2024 results: net income $13.8 million.

“Net Loss was $13.8 million for the first quarter 2024, compared to $41.9 million for the same period in 2023.”

Cepton, Inc. reported the first quarter 2024 ended March 31, 2024 results: revenue $1.9 million, net income $(6.8) million, or $(0.43) per share, basic and diluted, EPS $(0.43) per share, basic and diluted. Guidance reaffirmed.

“cloud simulation to expedite lidar-based ADAS and AV development at minimized physical implementation costs. Financial Highlights Revenue • First quarter 2024 total revenue was $1.9 million, consisting of $1.1 million product revenue and $0.8 million development revenue • First quarter 2024 total revenue increase by 31% compared to $1.5 million in the prior year”

ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2024.

“On May 13, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2024 financial results and providing a Company update.”

Annovis Bio, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update.”

Scorpius Holdings, Inc. reported the quarter ended March 31, 2024 results: revenue between $4.0 million and $5.0 million, net income net loss before income taxes from continuing operations to be between $4.0 million and $5.3 million.

“On a preliminary unaudited basis, for the quarter ended March 31, 2024, Scorpius Holdings, Ins. (the “Company”) expects to recognize between $4.0 million and $5.0 million of revenue. The Company expects its operating loss to be between $3.8 million and $5.1 million and net loss before income taxes from continuing operations to be between $4.0 million and $5.3 million.”

NEXGEL, INC. reported the quarter ended March 31, 2024 results: revenue $1.27 million, net income $905,000.

“as shall be expressly set forth by specific reference in such a filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year LANGHORNE, Pa. – May 13, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle,”

Leatt Corp reported first quarter ending March 31, 2024 results: revenue $10.61 million, net income $(816,679) or $(0.13) per basic and $(0.13) per diluted share, EPS $(0.13) per diluted share.

“results for the first quarter ending March 31, 2024. All financial numbers are in U.S. dollars. First Quarter 2024 and Recent Highlights • Revenues for the first quarter were $10.61 million, down 19%, compared to the first quarter of 2023. • Cash flows provided by operations for the first quarter were $2.83 million. • Income (loss) from operations for the first”

Tonix Pharmaceuticals Holding Corp. reported financial results for first quarter ended March 31, 2024.

“On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2024.”

iBio, Inc. reported financial results for third quarter ended March 31, 2024.

“On May 13, 2024, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

HARROW, INC. reported the first quarter ended March 31, 2024 results: revenue $34,587,000, net income (13,565,000), EPS (0.38). Guidance reaffirmed.

“First quarter 2024 figures of merit: For the Three Months Ended March 31, 2024 2023 Net revenues $ 34,587,000 $ 26,103,000 Gross margin 69 % 68 % Core gross margin (1) 76 % 76 % Net loss (13,565,000 ) (6,643,000 ) Core net loss (1) (9,789,000 ) (1,042,000 ) Adjusted EBITDA (1) 227,000 5,342,000 Basic and diluted net loss per share (0.38 ) (0.22 )”

Cocrystal Pharma, Inc. reported financial results for Q1 2024.

“Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.”

Milestone Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $10.4 million.

“Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024”

Forte Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income $(7,420 ), EPS $(0.16 ).

“On May 13, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.”

Eledon Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $10.3 million, EPS $0.34 per share.

“The Company reported a net loss of $10.3 million, or $0.34 per share, for the three months ended March 31, 2024, compared to a net loss of $10.8 million, or $0.75 per share, for the same period in 2023.”

FlexShopper, Inc. reported the quarter ended March 31, 2024 results: revenue $33.9 million, net income $(1.3) million, EPS $(0.06) per diluted share.

“Total revenues increased 10.1% to $33.9 million from $30.8 million ● Gross profit increased 30.9% to $17.8 million from $13.6 million ● Adjusted EBITDA 1 increased by $1.2 million to $7.6 million from $6.4 million ● Operating income increased 19.0% to $5.0 million from $4.2 million ● Net loss attributable to common stockholders of $(1.3) million, or $(0.06) per diluted share, compared to net loss attributable to common stockholders of $(1.2) million, or $(0.06) per diluted share”

BCP Investment Corp reported first quarter ended March 31, 2024 results: revenue $16.5 million, net income $6.2 million ($0.67 per share), EPS $0.67 per share.

“announced today its financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights • Total investment income for the first quarter of 2024 was $16.5 million (inclusive of the reversal $0.4 million, or $0.04 per share, of previously accrued income on two loans that were placed on non-accrual status in the first quarter), as compared”

SUTRO BIOPHARMA, INC. reported the quarter ended March 31, 2024 results: revenue $13.0 million, net income $267.6 million.

“stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $13.0 million for the quarter ended March 31, 2024, as compared to $12.7 million for the same period in 2023, with the 2024 amount related principally to the Astellas collaboration, and the”

Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income $30.7 million, EPS $(0.56) per basic and diluted share.

“or $(0.56) per basic and diluted share, compared to net loss of $26.7 million, or ($0.49) per basic and diluted share, for the same period in 2023. Revenues: Total revenue was $2.1 million and $6.2 million for the three months ended March 31, 2024 and 2023, respectively. Revenue primarily consisted of: · $0.8 million and $2.8 million of collaborative revenue”

Stereotaxis, Inc. reported First quarter ended March 31, 2024 results: revenue $6.9 million, net income ($4.5) million. Guidance reaffirmed.

“Revenue for the first quarter of 2024 totaled $6.9 million, growth of 5% from $6.5 million in the prior year first quarter. System revenue for the first quarter was $2.6 million and recurring revenue was $4.3 million, compared to $1.8 million and $4.7 million in the prior year first quarter, respectively. Gross margin for the first quarter of 2024 was 58% of revenue. Recurring revenue gross margin was 76% and system gross margin was 27%. Operating expenses in the first quarter of $8.7 million include $2.6 million in non-cash stock compensation expense. Excluding non-cash stock compensation expense, adjusted operating expenses in the quarter were $6.1 million, compared to $6.9 million for adjusted operating expenses in the prior year first quarter. Operating loss and net loss for the first quarter of 2024 were ($4.7) million and ($4.5) million, respectively, compared to ($5.6) million and ($5.3) million in the previous year.”

Kentucky First Federal Bancorp reported the nine months ended March 31, 2024 results: net income a net loss of $643,000, EPS ($0.08) diluted earnings per share.

“For the nine months ended March 31, 2024, the Company reported a net loss of $643,000 or ($0.08) diluted earnings per share compared to net earnings of $891,000 or $0.11 diluted earnings per share for the nine months ended March 31, 2023”

Kentucky First Federal Bancorp reported the three months ended March 31, 2024 results: net income a net loss of $107,000, EPS ($0.01) diluted earnings per share.

“Kentucky First Federal Bancorp (Nasdaq: KFFB), the holding company (the “Company”) for First Federal Savings and Loan Association of Hazard and First Federal Savings Bank of Kentucky, Frankfort, Kentucky, announced a net loss of $107,000 or ($0.01) diluted earnings per share for the three months ended March 31, 2024”

EXAGEN INC. reported the quarter ended March 31, 2024 results: revenue $14.4 million, net income $3.4 million. Guidance raised.

“leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: • Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023. • Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2%”

Vivani Medical, Inc. reported first quarter ended March 31, 2024 results: net income Net loss during the three months ended March 31, 2024 was $6.0 million.

“Net loss during the three months ended March 31, 2024 was $6.0 million”

Infinera Corp reported Fiscal year ended December 30, 2023 results: net income 53.4 million, EPS 0.23.

“GAAP revenue for the year was $1,614.1 million compared to $1,573.2 million in 2022. GAAP gross margin for the year was 38.6% compared to 34.1% in 2022. GAAP operating margin for the year was (0.3)% compared to (3.8)% in 2022. GAAP net loss for the year was $(25.2) million, or $(0.11) per diluted share, compared to $(76.0) million, or $(0.35) per diluted share, in 2022.”

Infinera Corp reported Fourth quarter ended December 30, 2023 results: net income 28.6 million, EPS 0.12.

“GAAP revenue for the quarter was $453.5 million compared to $392.4 million in the third quarter of 2023 and $485.9 million in the fourth quarter of 2022. GAAP gross margin for the quarter was 38.6% compared to 40.3% in the third quarter of 2023 and 37.1% in the fourth quarter of 2022. GAAP operating margin for the quarter was 2.5% compared to 2.0% in the third quarter of 2023 and 5.2% in the fourth quarter of 2022. GAAP net income for the quarter was $12.9 million, or $0.06 per diluted share, compared to net loss of $(9.4) million, or $(0.04) per diluted share, in the third quarter of 2023, and net income of $33.5 million, or $0.14 per diluted share, in the fourth quarter of 2022.”

CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2024.

“On May 13, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.”

TERAWULF INC. reported first quarter ended March 30, 2024 results: revenue $42.4 million.

“2024 Financial Results Self-mined 1,057 bitcoin in Q1 2024, an 8.9% increase over Q4 2023, on a total installed hashrate of 8.0 EH/s. Q1 2024 revenue grows 82.2% over Q4 2023 to $42.4 million. Q1 2024 Non-GAAP Adjusted EBITDA increases 95.4% over Q4 2023 to $32.0 million. Paid down approximately $63.6 million of debt so far in 2024, demonstrating the power of”

DURECT CORP reported three months ended March 31, 2024 results: revenue $1.8 million, net income $7.6 million.

“2b AHFIRM trial, which evaluated the safety and efficacy of larsucosterol as a treatment for patients with severe AH. Financial Highlights for Q1 2024: • Total revenues were $1.8 million and net loss was $7.6 million for the three months ended March 31, 2024 compared to total revenues of $2.1 million and net loss of $12.0 million for the three months ended March”

INOVIO PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.

“On May 13, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”

Track Group, Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $9.0 Million. Guidance reaffirmed.

“the Company posted (i) total revenue of $9.0 Million ("M"), an increase of approximately 8% over total revenue of $8.3M for the quarter ended March 31, 2023 ("Q2 FY23"); (ii) Q2 FY24 gross profit of $4.0M also representing an increase of approximately 6% over Q2 FY23 of $3.7M; (iii) Q2 FY24 operating loss of ($1.0M) compared to Q2 FY23 operating loss of ($0.9M); and (iv) net loss attributable to common shareholders of ($1.9M) in Q2 FY24 compared to ($1.5M) in Q2 FY23.”

LIVE VENTURES Inc reported fiscal second quarter ended March 31, 2024 results: revenue $118.6 million, net income Net loss was $3.3 million, EPS diluted loss per share was $1.04.

“Live Ventures Reports Fiscal Second Quarter 2024 Financial Results LAS VEGAS, May 13, 2024 -- Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its second fiscal quarter ended March 31, 2024. Fiscal Second Quarter 2024 Key Highlights: • Revenue increased 30.2% to $118.6 million, compared to $91.1 million in the prior year period • Net loss was $3.3 million and diluted loss per share was $1.04”

Ainos, Inc. reported first quarter ended March 31, 2024 results: revenue US$20,729, net income US$3,314,810.

“Revenues were US$20,729 in the first quarter of 2024, compared to US$49,164 in the same period of 2023, reflecting the Company’s cessation of sales of its COVID-19 antigen rapid test kits during the first quarter of 2024 after a strategic pivot shift.”

Intellicheck, Inc. reported first quarter ended March 31, 2024 results: revenue $4,680,000, net income ($442,000), EPS ($0.02) per diluted share.

“validation solutions, today announced its financial results for the first quarter ended March 31, 2024. Total revenue for the first quarter ended March 31, 2024 grew 10% to $4,680,000 compared to $4,254,000 in the same period of 2023. SaaS revenue grew 9% and totaled $4,609,000 compared to $4,228,000 in the same period of 2023. “Unrelenting incidents of”

ASTROTECH Corp reported third quarter of fiscal year 2024, which ended March 31, 2024 results: revenue $1.6 million.

“Highlights & Recent Developments ● Astrotech’s consolidated balance sheet remains strong with $34.7 million in cash and liquid investments. ● Year-to-date revenue totaled $1.6 million and was generated by sales of TRACER 1000TM explosive trace detector (ETD), as well as recurring maintenance services and sales of consumables for the TRACER 1000. The increase”

STRATTEC SECURITY CORP reported Third Quarter ended March 31, 2024 results: revenue $140,773 thousand, net income $1,506 thousand, EPS $0.37.

“Third Quarter Fiscal 2024 Financial Summary Third Quarter Ending Mar 31, 2024 Apr. 2, 2023 Inc (Dec) (Dollars in thousands, except per share data) Net Sales $ 140,773 $ 127,183 $ 13,590 Gross Profit $ 14,684 $ 10,001 $ 4,683 Gross Margin 10.4% 7.9% Operating Expenses $ 12,725 $ 12,485 $ 240 Operating Income (Loss) from Operations $ 1,959 $ (2,484) $ 4,443 Net Income (Loss) $ 1,506 $ (2,256) $ 3,762 Diluted Earnings (Loss) Per Share $ 0.37 $ (0.57) $ 0.94”

CBL & ASSOCIATES PROPERTIES INC reported financial results for first quarter ended March 31, 2024.

“On May 10, 2024, CBL & Associates Properties, Inc. (the "Company") reported its results for the first quarter ended March 31, 2024.”

TANDY LEATHER FACTORY INC reported first fiscal quarter of 2024 results: revenue $19.3 million, net income $0.5 million, EPS $0.06 per share.

“Highlights from First Quarter 2024: • Revenues were $19.3 million, down 5.3% from 2023 • Generated operating income of $0.7 million • Net income of $0.5 million, down from $0.7 million in 2023 • Gross margins of 56.7%, down from 58.1% in 2023 • Operating expenses $10.3 million, down 5.2% from 2023 • Adjusted EBITDA* of $1.1 million • Ended quarter with $12.3 million of cash and cash equivalents Tandy Leather Factory’s first quarter sales were $19.3 million in 2024, down from $20.4 million in 2023. First quarter 2024 gross profit was $10.9 million, down from $11.8 million in 2023. First quarter operating income was $0.7 million, down from $1.0 million in 2023. As of March 31, 2024, the Company held $12.3 million of cash and cash equivalents, up from $8.6 million a year earlier. The Company held inventory of $36.7 million, down from $38.0 million as of December 31, 2023. The Company had basic and diluted net income in the quarter of $0.06 per share, versus $0.08 in the prior year.”

ENBRIDGE INC updated its first quarter ended March 31, 2024 guidance (reaffirmed).

“We issued a press release on May 10, 2024 announcing our financial results for the first quarter ended March 31, 2024”

CRH PUBLIC LTD CO reported the fiscal quarter ended March 31, 2024 results: revenue $6.5bn, net income $114m, EPS $0.16. Guidance reaffirmed.

“shall be expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Q1 2024 Results Key Highlights Summary Financials Q1 2024 Change Total revenues $6.5bn +2% Net income 1 $114m 1 n/m 1 Net income margin 1.7% +220bps Adjusted EBITDA* $445m +15% Adjusted EBITDA margin* 6.8% +80bps EPS 1 $0.16 1 n/m 1 • Solid start to the year in”

E.W. SCRIPPS Co reported the quarter ended March 31, 2024 results: revenue Scripps reports Q1 2024 financial results May 9, 2024 CINCINNATI – The E.W. Scripps Company (NASDAQ: SSP) delivered $561, net income Loss attributable to the shareholders of Scripps was $12.8 million or 15 cents per share., EPS 15 cents per share. Guidance raised.

“Scripps reports Q1 2024 financial results May 9, 2024 CINCINNATI – The E.W. Scripps Company (NASDAQ: SSP) delivered $561 million in revenue for the first quarter of 2024. Loss attributable to the shareholders of Scripps was $12.8 million or 15 cents per share.”

OVERSEAS SHIPHOLDING GROUP INC reported the first quarter of 2024 results: revenue $117.5 million, net income $14.6 million, EPS $0.19 per diluted share.

“for the first quarter of 2024 was $43.9 million, an increase of $3.0 million, or 7.3%, from the first quarter of 2023. ● Shipping revenues for the first quarter of 2024 were $117.5 million, an increase of $3.7 million, or 3.3%, compared to the first quarter of 2023. ● Time charter equivalent (TCE) revenues (B) , a non-GAAP measure, for the first quarter of 2024”

BNB PLUS CORP. reported second fiscal quarter ended March 31, 2024 results: revenue approximately $930 thousand.

“reporting period. The Company will host an investor update call on June 12, 2024. Summary Second Quarter Fiscal 2024 Financial Results: ● Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter of fiscal 2023. The decrease in revenue of approximately $3.5 million was due to an”

GENCOR INDUSTRIES INC reported for the quarter ended March 31, 2024 results: revenue $40,676,000, net income $6,222,000, EPS $0.42.

“FISCAL 2024 RESULTS May 10, 2024 (PRIME NEWSWIRE) - Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American LLC: GENC) announced today net revenues increased 33.4% to $40,676,000 for the quarter ended March 31, 2024 compared with $30,501,000 for the quarter ended March 31, 2023. Gross profit margins for the quarter ended March 31, 2024 were 30.3% compared”

ATRION CORP reported first quarter ended March 31, 2024 results: revenue $47.3 million, net income $2.8 million, EPS $1.59.

“Atrion Reports First Quarter 2024 Results ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2024. Revenues for the first quarter of 2024 totaled $47.3 million compared to $40.0 million for the same period in 2023. For the just ended quarter, operating income was $3.1 million, down $1.3 million from the comparable 2023 period, primarily due to a one-time inventory write-off, and net income was $2.8 million, down $0.7 million from the same period in 2023. First quarter 2024 diluted earnings per share were $1.59 compared to $1.98 for the first quarter of 2023.”

AMERICAN VANGUARD CORP reported the first quarter ended March 31, 2024 results: revenue $135 million, net income $1.6 million, EPS $0.06. Guidance reaffirmed.

“(NYSE: AVD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights – versus First Quarter 2023: • Net sales of $135 million vs. $125 million • Adjusted EBITDA 1 of $15.5 million vs. $11.5 million • Operating Income of $6.1 million vs. $3.3 million • Net income of $1.6 million vs. $1.9 million •”

HARTE HANKS INC reported the first quarter ended March 31, 2024 results: revenue $45.4 million, net income $0.2 million, or $0.02 per basic and diluted share, EPS $0.02 per basic and diluted share.

“Company ended the quarter with a cash balance of $11.5 million at March 31, 2024. • Executing, as planned, the termination of Pension Plan 1. • Total revenues for Q1 2024 were $45.4 million, down 3.5% compared to $47.1 million in Q1 2023. • Operating income was $0.4 million compared to operating income of $1.1 million in the same quarter in the prior year. • Harte”